AR051288A1 - Derivados de pirazol condensado, su preparacion y su aplicacion terapeutica - Google Patents

Derivados de pirazol condensado, su preparacion y su aplicacion terapeutica

Info

Publication number
AR051288A1
AR051288A1 ARP050103775A ARP050103775A AR051288A1 AR 051288 A1 AR051288 A1 AR 051288A1 AR P050103775 A ARP050103775 A AR P050103775A AR P050103775 A ARP050103775 A AR P050103775A AR 051288 A1 AR051288 A1 AR 051288A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
radical
alkoxy
unsubstituted
Prior art date
Application number
ARP050103775A
Other languages
English (en)
Inventor
Francis Barth
Christian Congy
Murielle Rinaldi-Carmona
Claude Vernhet
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR051288A1 publication Critical patent/AR051288A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente se refiere a derivados de pirazol condensado, procedimientos de preparacion y aplicacion en terapéutica. Reivindicacion 1: Compuesto que responde a la formula (1) en la que: A representa un radical alquileno C3-5 lineal no sustituido o sustituido una o varias veces por un alquilo C1-3; un radical -CH2-CH2-O-CH2-; W representa un enlace directo o un radical -CH2-; R1 representa un átomo de H o un alquilo C1-3; R2 representa un alquilo C1-10 no sustituido o sustituido una o varias veces por un átomo de halogeno; un grupo -B-R4; R3 representa un fenilo sustituido por uno o varios sustituyentes elegidos independientemente entre un átomo de halogeno, un alquilo C1-4, un alcoxi C1-4, un radical trifluorometilo, un radical trifluorometoxi, un naftilo no sustituido o sustituido por uno o varios sustituyentes elegidos independientemente entre un átomo de halogeno, un alquilo C1-4, un alcoxi C1-4, un radical trifluorometilo; un quinolilo no sustituido o sustituido por uno o varios sustituyentes elegidos independientemente entre un átomo de halogeno, un alquilo C1-4, un alcoxi C1-4, un radical trifluorometilo; B representa un enlace directo o u radical alquileno C1-2 no sustituido o sustituido una o varias veces por un alquilo C1-3; R4 representa un fenilo no sustituido o sustituido por uno o varios sustituyentes elegidos independientemente entre un átomo de halogeno, un alquilo C1-4, un alcoxi C1-4, un radical trifluorometilo; un radical carbocíclico no aromático C3-12, no sustituido o sustituido una o varias veces por un alquilo C1-4 o un alcoxi C1-4; un 1,2,3,4-tetrahidronaftalen-1-ilo, en el estado de base, así como en el estado de hidrato o de solvato.
ARP050103775A 2004-09-13 2005-09-09 Derivados de pirazol condensado, su preparacion y su aplicacion terapeutica AR051288A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0409712A FR2875230A1 (fr) 2004-09-13 2004-09-13 Derives de pyrazole condense, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
AR051288A1 true AR051288A1 (es) 2007-01-03

Family

ID=34954413

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103775A AR051288A1 (es) 2004-09-13 2005-09-09 Derivados de pirazol condensado, su preparacion y su aplicacion terapeutica

Country Status (6)

Country Link
AR (1) AR051288A1 (es)
FR (1) FR2875230A1 (es)
PE (1) PE20060627A1 (es)
TW (1) TW200621786A (es)
UY (1) UY29112A1 (es)
WO (1) WO2006030124A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
EP1902034B1 (en) * 2005-06-02 2011-03-30 Glenmark Pharmaceuticals S.A. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
WO2007001939A1 (en) * 2005-06-27 2007-01-04 Janssen Pharmaceutica N.V. Tetrahydro-pyranopyrazole compounds displaying cannabinoid modulating activities
US8378117B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
KR20080050522A (ko) * 2005-09-23 2008-06-05 얀센 파마슈티카 엔.브이. 헥사하이드로-사이클로헵타피라졸 카나비노이드 모듈레이터
US7825151B2 (en) 2005-09-23 2010-11-02 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators
WO2007038045A1 (en) * 2005-09-23 2007-04-05 Janssen Pharmaceutica, N.V. Tetrahydro-indazolyl cannabinoid modulators
EP1937646A1 (en) * 2005-09-23 2008-07-02 Janssen Pharmaceutica N.V. Tetrahydro-cyclopentyl pyrazole cannabinoid modulators
NZ567006A (en) * 2005-09-23 2010-11-26 Janssen Pharmaceutica Nv Hexahydro cyclooctyl pyrazole cannabinoid modulators
US8378096B2 (en) 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
US7795294B2 (en) 2006-02-14 2010-09-14 Janssen Pharmaceutica N.V. Tetrahydro-2H-indazole pyrazole cannabinoid modulators
US20070254911A1 (en) * 2006-03-27 2007-11-01 Mingde Xia Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
KR20090120499A (ko) * 2007-03-21 2009-11-24 얀센 파마슈티카 엔.브이. Cb2 수용체 매개 통증의 치료 방법
WO2008115672A1 (en) * 2007-03-21 2008-09-25 Janssen Pharmaceutica N.V. Method for treating cb2 receptor mediated pain
WO2009119088A1 (ja) * 2008-03-25 2009-10-01 武田薬品工業株式会社 複素環化合物
KR101787116B1 (ko) * 2009-01-28 2017-10-18 케러 테라퓨틱스, 인코포레이티드 바이시클릭 피라졸로-헤테로사이클
KR101749778B1 (ko) * 2009-08-28 2017-06-21 아레나 파마슈티칼스, 인크. 칸나비노이드 수용체 조절제
CN102762575B (zh) 2009-12-04 2015-04-15 桑诺维恩药品公司 多环化合物及其使用方法
JP6043733B2 (ja) 2011-02-25 2016-12-14 アリーナ ファーマシューティカルズ, インコーポレイテッド カンナビノイド受容体モジュレーター
US9458136B2 (en) * 2011-02-25 2016-10-04 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of cannabinoid receptor modulators
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
WO2012116278A1 (en) * 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
ES2620316T3 (es) * 2012-05-11 2017-06-28 Bayer Pharma Aktiengesellschaft Cicloalquenopirazoles sustituidos como inhibidores de BUB1 para el tratamiento del cáncer
CA3010615C (en) 2016-01-14 2024-02-20 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
US10196403B2 (en) 2016-07-29 2019-02-05 Sunovion Pharmaceuticals Inc. Compounds and compositions and uses thereof
JP2019523279A (ja) 2016-07-29 2019-08-22 サノビオン ファーマシューティカルズ インクSunovion Pharmaceuticals Inc. 化合物および組成物ならびにそれらの使用
US11129807B2 (en) 2017-02-16 2021-09-28 Sunovion Pharmaceuticals Inc. Methods of treating schizophrenia
BR112020001433A2 (pt) 2017-08-02 2020-07-28 Sunovion Pharmaceuticals Inc. compostos de isocromano e usos dos mesmos
CA3091292A1 (en) 2018-02-16 2019-08-22 Sunovion Pharmaceuticals Inc. Salts, crystal forms, and production methods thereof
US11136304B2 (en) 2019-03-14 2021-10-05 Sunovion Pharmaceuticals Inc. Salts of a heterocyclic compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
TWI768464B (zh) * 2019-09-12 2022-06-21 大陸商四川海思科製藥有限公司 三環吡唑衍生物及其製備
WO2021047581A1 (zh) * 2019-09-12 2021-03-18 四川海思科制药有限公司 一种六氢化苯并吡唑衍生物及其制备
US11738002B2 (en) 2020-04-14 2023-08-29 Sunovion Pharmaceuticals Inc. Methods of treating neurological and psychiatric disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2742148B1 (fr) * 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2800375B1 (fr) * 1999-11-03 2004-07-23 Sanofi Synthelabo Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
AU2001234958A1 (en) * 2000-02-11 2001-08-20 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
WO2003035005A2 (en) * 2001-10-26 2003-05-01 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
EP1735286B1 (en) * 2004-03-24 2012-01-04 Janssen Pharmaceutica NV Tetrahydro-indazole cannabinoid modulators

Also Published As

Publication number Publication date
FR2875230A1 (fr) 2006-03-17
WO2006030124A1 (fr) 2006-03-23
UY29112A1 (es) 2006-04-28
PE20060627A1 (es) 2006-08-15
TW200621786A (en) 2006-07-01

Similar Documents

Publication Publication Date Title
AR051288A1 (es) Derivados de pirazol condensado, su preparacion y su aplicacion terapeutica
CR11596A (es) Derivados de urea de tetrahidroquinoxalina, su preparacion y su aplicacion en terapeutica
ATE302775T1 (de) Carbolinderivate
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
UY29388A1 (es) Derivados del (1,5-difenil-h-pirazol-3-il)oxadiazol, su preparación y su aplicacion en terapéutica.
RS52534B (en) MACROCYCLIC COMPOUNDS OF HINOXALINE AS HCV NS3 PROTEASE INHIBITORS
AR057705A1 (es) 3-acilaminobenzanilidas insecticidas
PT1332137E (pt) Tratamento de tumores estromais gastrintestinais
EA201001124A1 (ru) Производные хинолина и их применение в качестве фунгицидов
RS53209B (en) PHARMACEUTICAL COMPOSITION FOR VIRAL HEPATITIS C PROTEASE INHIBITOR
CY1107846T1 (el) Παραγωγα κιναζολινονης χρησιμα ως βανιλλοειδεις ανταγωνιστες
AR053774A1 (es) Derivados de sulfonilbencimidazol. composiciones farmaceuticas.
ATE346067T1 (de) Carbolinderivate
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
HRP20080529T3 (en) Amide prodrug of gemcitabine, compositions and use thereof
CY2015007I1 (el) Ενωσεις, συνθεσεις και χρησεις παραγωγων βενζοθειαζολης
ATE377419T1 (de) Substituierte 4-alkoxyoxazol derivate als ppar agonisten
EA200700997A1 (ru) 2,5- и 2,6-дизамещенные аналоги бензазола, полезные в качестве ингибиторов протеинкиназ
HRP20080447T3 (en) 7-(2-(4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydro-pyrid-1-yl)ethyl) isoquinoline besylate salt, preparation and therapeutic use thereof
AR057929A1 (es) Compuestos de amidinfenilo y su uso como fungicidas
DE602004024830D1 (de) Die hiv-protease inhibierende sulfonamide
NO20080265L (no) 2-(1H-indolylsulfanyl)-arylaminderivater
DE60220325D1 (de) Substituierte Carbostyrilderivate als 5-HT1A-Subtyp Agonisten
SE0103710D0 (sv) Compounds
RS52381B (en) 2-METHYL-1- (PHENYLSULPHONYL) -4- (PIPERAZIN-1-IL) -1H-BENZIMIDAZOLE KAO 5-HYDROXYTRIPAMINE-6 LIGAND

Legal Events

Date Code Title Description
FA Abandonment or withdrawal